Open AccessPretreatment by omalizumab allows allergen‐specific immunotherapy in children and young adult with severe allergic asthma
Author(s) -
Lambert Nathalie,
Guiddir Tamazoust,
Just Jocelyne,
Amat Flore
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s2-p1
Subject(s) - omalizumab , medicine , asthma , discontinuation , exacerbation , allergic asthma , allergy , allergen immunotherapy , pediatrics , allergen , immunology , immunoglobulin e , antibody
Background Subcutaneous allergen-specific immunotherapy (SCIT) is a valuable treatment option for patients with controlled mild to moderate allergic asthma However, SCIT is contraindicated for patients with severe persistent asthma due to a potential systemic allergic reaction. Several studies in adolescents and adults with persistent allergic rhinitis and moderate persistent allergic asthma have shown that SCIT is better tolerated when combined with. Nevertheless, no previous studies have been conducted in children and adolescents with severe asthma to assess the safety and efficacy of a combination treatment of SCIT and omalizumab.